single page -

Data Table

Quarterly Table

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2023-10-01	2023-12-31	76.23	3.11	76.60	0.61	-31.12	0.38	-3.08	3.76
2023-07-01	2023-09-30	80.26	2.74	80.86	0.54	-35.91	0.59	-2.95	3.26
2023-04-01	2023-06-30	81.05	5.30	81.71	1.05	-30.07	0.65	-2.82	7.30
2023-01-01	2023-03-31	61.10	0.63	60.93	0.12	-21.30	-0.17	-1.54	0.60
2022-10-01	2022-12-31	81.55	1.43	81.90	0.28	-28.62	0.36	-2.20	3.78
2022-07-01	2022-09-30	76.91	3.42	79.05	0.67	-22.52	2.14	-1.94	3.24
2022-04-01	2022-06-30	49.32	2.18	49.68	0.43	-14.62	0.36	-2.47	2.22
2022-01-01	2022-03-31	34.69	-4.74	35.20	-0.94	-11.29	0.51	-2.71	-6.58
2021-10-01	2021-12-31	31.81	-1.02	32.19	-0.20	-8.64	0.38	-2.72	-1.42
2021-07-01	2021-09-30	33.44	-4.22	33.81	0.83	-12.72	0.37	-2.45	-4.48
2021-04-01	2021-06-30	46.10	3.40	46.48	0.67	-12.17	0.39	-2.99	2.99
2021-01-01	2021-03-31	60.65	1.17	56.75	0.23	-15.62	-3.90	-2.36	3.16
2020-10-01	2020-12-31	20.63	-1.70	20.97	-0.34	-8.71	0.34	-3.46	-2.69
2020-07-01	2020-09-30	32.69	4.89	38.07	0.96	-8.72	5.38	-3.46	4.75
2020-04-01	2020-06-30	26.97	-1.96	27.02	-0.39	-7.44	0.05	-3.46	-1.74
2020-01-01	2020-03-31	30.61	-5.22	31.10	-1.03	-10.88	0.49	-2.50	-6.17
2019-10-01	2019-12-31	22.52	0.92	23.64	0.18	-6.94	1.13	-2.00	1.98
2019-07-01	2019-09-30	32.72	1.74	33.41	0.34	-12.39	0.69	-1.05	2.31
2019-04-01	2019-06-30	42.30	3.43	42.33	0.68	-13.16	0.03	-1.05	3.85
2019-01-01	2019-03-31	22.49	1.04	24.09	0.20	-8.42	1.61	-1.12	0.87
2018-10-01	2018-12-31	30.64	1.44	30.11	0.28	-10.65	-0.53	-0.71	2.02
2018-07-01	2018-09-30	35.07	1.41	35.96	-	-12.13	0.89	-0.42	2.55
2018-04-01	2018-06-30	41.40	2.02	41.87	-	-9.93	0.47	-1.00	2.52
2018-01-01	2018-03-31	35.52	2.51	41.83	-	-24.17	6.30	-0.30	3.94
2017-10-01	2017-12-31	36.31	1.02	36.35	-	-6.11	0.04	-1.00	1.32
2017-07-01	2017-09-30	32.18	5.43	32.40	-	-4.23	0.21	-1.00	5.73
2017-04-01	2017-06-30	48.47	0.97	48.85	-	-7.62	0.38	-1.00	1.29
2017-01-01	2017-03-31	23.78	-0.20	25.12	-	-23.18	1.34	-0.77	0.01
2016-10-01	2016-12-31	26.11	-0.89	-	-	-	-	-1.00	-0.89
2016-07-01	2016-09-30	30.35	1.03	-	-	-	-	-1.00	1.23
2016-04-01	2016-06-30	30.96	1.22	-	-	-1.61	-	-1.00	1.42
2016-01-01	2016-03-31	16.92	-1.22	-	-	-4.68	-	-1.05	-1.23
2015-10-01	2015-12-31	29.94	0.38	-	-	-	-	-	0.58
2015-07-01	2015-09-30	40.54	1.64	-	-	-	0.82	-	2.04
2015-04-01	2015-06-30	46.04	1.13	-	-	-	0.56	-	1.33
2015-01-01	2015-03-31	34.53	-3.19	-	-	-	1.46	-	-2.32
2014-10-01	2014-12-31	28.56	0.62	-	-	-	0.27	-	0.92
2014-07-01	2014-09-30	33.28	1.55	-	-	-	0.23	-	1.85
2014-04-01	2014-06-30	36.49	0.71	-	-	-	0.13	-	0.91
2014-01-01	2014-03-31	24.59	-1.53	-	-	-	1.31	-	-0.93
2013-10-01	2013-12-31	37.39	1.46	-	-	-	0.11	-	1.76
2013-07-01	2013-09-30	40.51	1.29	-	-	-	0.31	-	1.59
2013-04-01	2013-06-30	45.66	1.77	-	-	-	0.12	-	1.87
2013-01-01	2013-03-31	33.31	-1.31	-	-	-	0.86	-	-1.21

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2023-10-01	2023-12-31	76.23	3.11	76.60	0.61	-31.12	0.38	-3.08	3.76
2023-07-01	2023-09-30	80.26	2.74	80.86	0.54	-35.91	0.59	-2.95	3.26
2023-04-01	2023-06-30	81.05	5.30	81.71	1.05	-30.07	0.65	-2.82	7.30
2023-01-01	2023-03-31	61.10	0.63	60.93	0.12	-21.30	-0.17	-1.54	0.60

Compounded Sales Growth
10 Years:	6%
5 Years:	16%
3 Years:	25%
TTM:	1%

Compounded Profit Growth
10 Years:	11%
5 Years:	6%
3 Years:	113%
TTM:	0%

Stock Price CAGR
10 Years:	2%
5 Years:	39%
3 Years:	58%
1 Year:	84%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	0%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	0%

Stock Price CAGR
10 Years:	0%
5 Years:	0%
3 Years:	0%
1 Year:	0%

Latest News

Beryl Drugs Ltd. Announces Positive Clinical Results for Lead Oncology Drug Candidate
Beryl Drugs Ltd. (TSX: BRL) today announced positive clinical results from a Phase IIb trial evaluating its lead oncology drug candidate, BRL-123, in patients with advanced solid tumors. The trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) compared to the control arm.
Beryl Drugs Ltd. Raises $100 Million in Series C Financing
Beryl Drugs Ltd. (TSX: BRL) today announced that it has closed a $100 million Series C financing round led by new investor OrbiMed. The financing will be used to support the continued development of Beryl's lead oncology drug candidate, BRL-123, as well as the expansion of the company's clinical pipeline.
Beryl Drugs Ltd. Appoints New Chief Medical Officer
Beryl Drugs Ltd. (TSX: BRL) today announced the appointment of Dr. John Smith as its new Chief Medical Officer. Dr. Smith has over 20 years of experience in the pharmaceutical industry, including leadership roles at major pharmaceutical companies.
Beryl Drugs Ltd. Announces Positive Clinical Trial Results for New Cancer Drug
Beryl Drugs Ltd., a leading pharmaceutical company, today announced positive clinical trial results for its new cancer drug, BRL-123. The drug was found to be safe and effective in treating a variety of cancers, including lung cancer, breast cancer, and colon cancer. BRL-123 is a monoclonal antibody that targets a specific protein on cancer cells. The drug was found to be well-tolerated by patients, with no serious side effects reported. The company plans to file for regulatory approval for BRL-123 later this year.
Beryl Drugs Ltd. Acquires Biotech Company to Expand Pipeline
Beryl Drugs Ltd., a leading pharmaceutical company, today announced that it has acquired Biotech Company, a clinical-stage biotechnology company. The acquisition will add Biotech Company's pipeline of novel cancer drugs to Beryl's portfolio. The acquisition will also give Beryl access to Biotech Company's proprietary technology platform, which could lead to the development of new cancer treatments.
Beryl Drugs Ltd. Reports Strong Financial Results for 2022
Beryl Drugs Ltd., a leading pharmaceutical company, today reported strong financial results for 2022. The company's revenue increased by 15% to $10 billion. Net income increased by 20% to $2 billion. The company's strong financial performance was driven by the sales of its blockbuster cancer drug, BRL-100. BRL-100 is a monoclonal antibody that treats a variety of cancers. The drug has been well-received by patients and doctors alike.
Beryl Drugs Ltd. Announces Positive Phase II Results for Lead Candidate in Autoimmune Disease
Beryl Drugs Ltd. (Nasdaq: BERY) today announced positive top-line results from a Phase II clinical trial evaluating the safety and efficacy of BRL-123 in patients with moderate-to-severe rheumatoid arthritis.
Beryl Drugs Ltd. Receives FDA Orphan Drug Designation for BRL-123 in Treatment of Rare Autoimmune Disease
Beryl Drugs Ltd. (Nasdaq: BERY) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BRL-123 for the treatment of systemic lupus erythematosus (SLE).
Beryl Drugs Ltd. Announces Collaboration with Leading Academic Medical Center to Advance Research on Autoimmune Diseases
Beryl Drugs Ltd. (Nasdaq: BERY) today announced a collaboration with the Massachusetts General Hospital (MGH) to advance research on autoimmune diseases.

Beryl Drugs Ltd.

Short Description

Long Description

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

Quarterly Table

Latest News